Tenderwize
Wróć do wyszukiwania

Open-house rebate agreements for Tocilizumab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 05, 2026 · 69 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

58 / 100

Czynniki ryzyka

Paper submissions require two original signed copies and timely receipt of the originals by the 10th of the month after...

Participation is limited to pharmaceutical companies and requires a signed declaration of reliability.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Non-exclusive supply/rebate agreement for Tocilizumab, ATC L04AC07.
  • Open-house model with identical, non-individually negotiable contract terms.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement for Tocilizumab (ATC L04AC07) offered by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract can start from 2025-01-01, runs until 2026-12-31, and applications can be submitted until 2026-11-05 11:00. No contract value is stated.

Ryzyka

Paper submissions require two original signed copies and timely receipt of the originals by the 10th of the month after...

Participation is limited to pharmaceutical companies and requires a signed declaration of reliability.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreements for Tocilizumab

Single lot covering non-exclusive open-house rebate agreements for the pharmaceutical product Tocilizumab, ATC L04AC07. The lot is for supplies in Germany, with performance in Bavaria (DE212). The procedure is open-house, with no selection among bidders and identical contract terms for all eligible pharmaceutical companies. Lot information comes from structured data and the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Dec 2024 - Dec 2026

Kategoria

Pharmaceutical products

Termin

Deadline Nov 05, 2026

Szczegóły zamówienia

Data publikacji
17 Nov 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
701022-2024

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30